{"id":551265,"date":"2026-04-01T22:50:07","date_gmt":"2026-04-01T20:50:07","guid":{"rendered":"https:\/\/medizinonline.com\/new-therapeutic-standards-with-shr-a-1811\/"},"modified":"2026-04-01T22:50:41","modified_gmt":"2026-04-01T20:50:41","slug":"new-therapeutic-standards-with-shr-a-1811","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-therapeutic-standards-with-shr-a-1811\/","title":{"rendered":"New therapeutic standards with SHR-A 1811"},"content":{"rendered":"\n

This year’s ESMO Congress 2025 once again offered a wide range of new data on the treatment of HER2-positive breast cancer, including the interim analysis of the phase 3 HORIZON-Breast01 study presented by Erwei Song (Sun Yat-sen University, Guangzhou). The study compares SHR-A 1811 with pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer. It provides the first randomized data on this new HER2-targeted antibody-drug conjugate. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

This year’s ESMO Congress 2025 once again offered a wide range of new data on the treatment of HER2-positive breast cancer, including the interim analysis of the phase 3 HORIZON-Breast01……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":551267,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"HER2+ metastatic breast cancer ","footnotes":""},"category":[11513,11400,11370,11548,11503],"tags":[13554,17491,22510,90034,90014,90019,90022,89983,89982,90024,89979,89981,90027,89980,90031,90011],"powerkit_post_featured":[],"class_list":["post-551265","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-gynecology","category-oncology","category-rx-en","category-studies","tag-breast-cancer-en","tag-capecitabine","tag-esmo-en","tag-esmo-congress-2025","tag-her2-positive-metastatic-breast-cancer","tag-interim-analysis-phase-3-study-horizon-breast01","tag-novel-her2-targeted-antibody-drug-conjugates","tag-pehdra-study","tag-phase-1-study-horizon-x","tag-phoebe-study","tag-pyrotinib","tag-pyrotinib-plus-capecitabine","tag-sequencing-of-her2-directed-therapies","tag-shr-a-1811","tag-shr-a1811-trastuzumab-rezetecan","tag-side-effect-profile-shr-a-1811-vs-pyrotinib-capecitabine","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-17 02:13:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":551269,"slug":"de-nouvelles-references-therapeutiques-grace-a-shr-a-1811","post_title":"De nouvelles r\u00e9f\u00e9rences th\u00e9rapeutiques gr\u00e2ce \u00e0 SHR-A 1811","href":"https:\/\/medizinonline.com\/fr\/de-nouvelles-references-therapeutiques-grace-a-shr-a-1811\/"},"it_IT":{"locale":"it_IT","id":551270,"slug":"nuovi-standard-terapeutici-con-shr-a-1811","post_title":"Nuovi standard terapeutici con SHR-A 1811","href":"https:\/\/medizinonline.com\/it\/nuovi-standard-terapeutici-con-shr-a-1811\/"},"pt_PT":{"locale":"pt_PT","id":551276,"slug":"novos-padroes-terapeuticos-com-o-shr-a-1811","post_title":"Novos padr\u00f5es terap\u00eauticos com o SHR-A 1811","href":"https:\/\/medizinonline.com\/pt-pt\/novos-padroes-terapeuticos-com-o-shr-a-1811\/"},"es_ES":{"locale":"es_ES","id":551287,"slug":"nuevos-estandares-terapeuticos-con-shr-a-1811","post_title":"Nuevos est\u00e1ndares terap\u00e9uticos con SHR-A 1811","href":"https:\/\/medizinonline.com\/es\/nuevos-estandares-terapeuticos-con-shr-a-1811\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/551265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=551265"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/551265\/revisions"}],"predecessor-version":[{"id":551278,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/551265\/revisions\/551278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/551267"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=551265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=551265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=551265"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=551265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}